Analysts Anticipate VBI Vaccines Inc (NASDAQ:VBIV) to Announce -$0.05 EPS

Wall Street brokerages predict that VBI Vaccines Inc (NASDAQ:VBIV) will post earnings of ($0.05) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for VBI Vaccines’ earnings, with estimates ranging from ($0.05) to ($0.04). VBI Vaccines reported earnings of ($0.13) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 61.5%. The firm is expected to issue its next earnings results on Friday, August 14th.

According to Zacks, analysts expect that VBI Vaccines will report full year earnings of ($0.19) per share for the current fiscal year, with EPS estimates ranging from ($0.22) to ($0.16). For the next fiscal year, analysts expect that the firm will post earnings of ($0.19) per share, with EPS estimates ranging from ($0.22) to ($0.15). Zacks’ EPS averages are a mean average based on a survey of research firms that cover VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.83 million. VBI Vaccines had a negative return on equity of 57.79% and a negative net margin of 2,133.79%.

VBIV has been the subject of a number of recent analyst reports. BidaskClub raised shares of VBI Vaccines from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 18th. Zacks Investment Research lowered shares of VBI Vaccines from a “strong-buy” rating to a “hold” rating in a report on Thursday. Canaccord Genuity reiterated a “buy” rating and issued a $4.00 price target on shares of VBI Vaccines in a research note on Friday, March 6th. Finally, Oppenheimer boosted their price objective on VBI Vaccines from $5.00 to $8.00 and gave the company an “outperform” rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. VBI Vaccines has a consensus rating of “Buy” and an average price target of $4.13.

Shares of VBIV traded up $0.23 during trading on Friday, reaching $2.99. The company’s stock had a trading volume of 37,257,365 shares, compared to its average volume of 9,694,090. The company has a market cap of $636.59 million, a price-to-earnings ratio of -8.54 and a beta of 1.70. The company has a quick ratio of 1.28, a current ratio of 1.30 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $2.20 and a two-hundred day moving average of $1.47. VBI Vaccines has a twelve month low of $0.47 and a twelve month high of $3.50.

In other VBI Vaccines news, major shareholder Life Sciences Maste Perceptive acquired 9,090,909 shares of the stock in a transaction that occurred on Friday, April 24th. The stock was acquired at an average price of $1.21 per share, with a total value of $10,999,999.89. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in VBIV. Rhumbline Advisers increased its position in VBI Vaccines by 11.5% in the fourth quarter. Rhumbline Advisers now owns 70,975 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 7,328 shares during the period. Oppenheimer & Co. Inc. lifted its position in VBI Vaccines by 64.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 26,200 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 10,300 shares during the last quarter. Citigroup Inc. grew its position in VBI Vaccines by 35.7% in the 1st quarter. Citigroup Inc. now owns 52,170 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 13,716 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of VBI Vaccines by 61.3% during the first quarter. BNP Paribas Arbitrage SA now owns 47,345 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 17,995 shares during the period. Finally, Cetera Advisor Networks LLC increased its position in VBI Vaccines by 95.1% in the 4th quarter. Cetera Advisor Networks LLC now owns 38,602 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 18,815 shares during the period. Institutional investors and hedge funds own 33.88% of the company’s stock.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Featured Story: What is quantitative easing?

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.